Metabotropic glutamate receptors as targets for novel anxiolytics

Current Opinion in Pharmacology
Francesco Ferraguti

Abstract

Anxiety disorders are highly prevalent psychiatric illnesses posing an important social and economic burden. Their current pharmacotherapy shows short term efficacy, though nearly one third of patients do not achieve sustained remission. There is, therefore, a strong medical need for new therapeutic agents acting through novel mechanisms of action. Considerable work has focused on metabotropic glutamate (mGlu) receptors as potential targets for novel anxiolytics. Ligands acting at mGlu receptors showed promising results in preclinical studies, whereas their efficacy was dubious in clinical trials. Recent preclinical and clinical studies have opened new prospects for targeting mGlu receptors to treat anxiety disorders. This review provides an outlook on these progresses.

Citations

May 9, 2019·Pharmacology Research & Perspectives·Tyler W McCullock, Paul J Kammermeier
Mar 16, 2019·Frontiers in Molecular Neuroscience·Arnau Ramos-PratsFrancesco Ferraguti
Jan 9, 2019·Frontiers in Behavioral Neuroscience·Catherine M DesrumauxLaurent Lagrost
Aug 31, 2019·Pharmacology & Therapeutics·Simone B Sartori, Nicolas Singewald
Sep 14, 2019·Behavioural Brain Research·Ewa Siucinska
Jan 27, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gabriela P SiloteVanessa Beijamini
Aug 8, 2021·International Journal of Molecular Sciences·Luca ZangrandiArnau Ramos-Prats

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.